Earnings Call
Apr 22, 2026
Q1 FY2026
EPS Estimate
11.03
EPS Actual
12.58
Post-Earnings Close
$328.20
Earnings Reaction
+0.0%
Elevance Health opened 2026 with a quarter that materially exceeded internal expectations, reporting adjusted diluted EPS of $12.58 against a consensus estimate of $11.03. The beat was driven by three distinct sources: favorable underlying claims experience across health benefits (roughly $0.30 of core outperformance), ACA bronze-plan seasonality that defers costs into the back half ($0.15), and approximately $1.00 per share from nonrecurring valuation adjustments within net investment income. Management was explicit that the $1.00 nonrecurring item should be excluded from the 2026 earnings baseline for purposes of modeling 2027 growth, setting that baseline at $25.75. Full-year adjusted EPS guidance was raised to at least $26.75, and the company reiterated confidence in at least 12% adjusted EPS growth in 2027 off that revised base.
Report generated on Apr 22, 2026
AI-generated earnings analysis. Not investment advice.
Chief Executive Officer
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
Read the full ELV analysis
The complete report, with key themes, analyst Q&A summary, notable quotes, and market context — is free with an account. No password, no card.